Search Results

CLINICAL TRIAL LAUNCHED TO TEST FIRST OF ITS KIND DRUG FOR AMD AND DME

Fighting Blindness Canada funded researcher Dr. Sachdev Sidhu (University of Waterloo) has developed a novel antibody therapy that will now be tested in a Phase 1/2 human clinical trial (Clinical Trial ID:...

CLINICAL TRIAL ADVANCES FOR IRD, AMD AND GLAUCOMA

From April 23-27, Fighting Blindness Canada attended one of the largest vision research conferences in the world: the Association for Research in Vision and Ophthalmology (ARVO). It was illuminating to learn about...

NAC ATTACK: A PHASE III CLINICAL TRIAL TO TEST AN ORAL THERAPY FOR RETINITIS PIGMENTOSA

Starting in 2023, a new clinical trial called NAC Attack will be launched to test an oral medication, N-acetylcysteine (NAC), as a potential therapy for patients with retinitis pigmentosa (RP). NAC Attack...

FBC-FUNDED RESEARCHER BRINGING NEW CLINICAL TRIAL TO CANADA

This month, we’re pleased to announce that Dr. Robert Koenekoop—a long-time FBC-funded researcher—will be bringing a natural history clinical trial to Canada focused on developing an effective treatment for Usher syndrome caused...

NEW GENE THERAPY CLINICAL TRIAL IN CANADA FOR BLINDING EYE DISEASE

One of our core goals at Fighting Blindness Canada is to accelerate the development of new sight-saving treatments. Lately, we have been writing a lot about the exciting progress in gene therapy,...

CLINICAL TRIAL UPDATES: GENE THERAPY

Many experts agree that gene replacement therapy is a novel approach to treating inherited degenerative retinal diseases, especially when the disease is caused by a single gene defect (or mutation). Gene replacement...